What are the clinical translational implications of the results reported thus far from the CAHtalyst trial, and how might you identify patients in which crinecerfont would address unmet therapeutic need?

Name: What are the clinical translational implications of the results reported thus far from the CAHtalyst trial, and how might you identify patients in which crinecerfont would address unmet therapeutic need?
Uploaded: 2024-11-30T00:00:00+00:00

CLICK HERE FOR CME CREDIT Back to Symposium

Created by

Presenter

Patricia Fechner, MD

Medical Director, DSD Program
Medical Director, CAH Program
Co-Director, Turner Syndrome Clinic
Seattle Children’s Hospital
Professor of Pediatrics
University of Washington School of Medicine
Seattle, WA